The Fact About New advancements in BRD4 inhibition therapy ABBV-744 That No One Is Suggesting
In Segment C, members will receive ABBV-744 and oral navitoclax. In Section D, contributors will acquire ABBV-744 and ruxolitinib. Participants will get treatment until sickness progression or perhaps the contributors are unable to tolerate the study drugs.Probable new strategies for that diagnosis and treatment of AML. (A) The identification of Tr